Simvastatin attenuates the additive effects of TNF-α and IL-18 on the connexin 43 up-regulation and over-proliferation of cultured aortic smooth muscle cells

Cytokine

Volumn 62, Issue 3, 2013, Pages 341-351

  Lin, Yu Chun ^a   Chiang, Chiang Hua ^b   Chang, Li Teh ^c   Sun, Cheuk Kwan ^a   Leu, Steve ^d   Shao, Pei Lin ^d   Hsieh, Ming Chu ^a   Tsai, Tzu Hsien ^d   Chua, Sarah ^d   Chung, Sheng Ying ^d   Kao, Ying Hsien ^a   Yip, Hon Kan ^d  

^a I SHOU UNIVERSITY   (Taiwan)

^b NATIONAL PINGTUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^c MEIHO UNIVERSITY   (Taiwan)

^d CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Aortic smooth muscle cells; Connexin 43; Interleukin 18; PI3K Akt signaling; Tumor necrosis factor

Indexed keywords

CONNEXIN 43; EZETIMIBE PLUS SIMVASTATIN; INTERLEUKIN 18; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA; AZETIDINE DERIVATIVE; DRUG COMBINATION; EZETIMIBE, SIMVASTATIN DRUG COMBINATION; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA MEDIA; ARTICLE; ATHEROMA; CELL INFILTRATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; HYPERCHOLESTEROLEMIA; MACROPHAGE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SMOOTH MUSCLE FIBER; TREATMENT RESPONSE; UPREGULATION; ANIMAL; AORTA; APOPTOSIS; CELL CULTURE; DRUG COMBINATION; DRUG EFFECTS; DRUG POTENTIATION; ENZYMOLOGY; LIPID DIET; METABOLISM; NEOINTIMA; PATHOLOGY; RABBIT; RAT; SIGNAL TRANSDUCTION;

ANIMALIA; ORYCTOLAGUS CUNICULUS;

ANIMALS; AORTA; APOPTOSIS; AZETIDINES; CELL PROLIFERATION; CELLS, CULTURED; CONNEXIN 43; DIET, HIGH-FAT; DOWN-REGULATION; DRUG COMBINATIONS; DRUG SYNERGISM; HYPERCHOLESTEROLEMIA; INTERLEUKIN-18; MACROPHAGES; MYOCYTES, SMOOTH MUSCLE; NEOINTIMA; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; RABBITS; RATS; SIGNAL TRANSDUCTION; SIMVASTATIN; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 84877802805     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2013.04.003     Document Type: Article

References (33)

1. Hansson G.K., Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 2006, 6:508-519.
2. Kleemann R., Zadelaar S., Kooistra T. Cytokines and atherosclerosis: a comprehensive review of studies in mice. Cardiovasc Res 2008, 79:360-376.
3. Young J.L., Libby P., Schonbeck U. Cytokines in the pathogenesis of atherosclerosis. Thromb Haemost 2002, 88:554-567.
4. Haefliger J.A., Nicod P., Meda P. Contribution of connexins to the function of the vascular wall. Cardiovasc Res 2004, 62:345-356.
5. Brisset A.C., Isakson B.E., Kwak B.R. Connexins in vascular physiology and pathology. Antioxid Redox Signal 2009, 11:267-282.
6. Blackburn J.P., Peters N.S., Yeh H.I., Rothery S., Green C.R., Severs N.J. Upregulation of connexin43 gap junctions during early stages of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 1995, 15:1219-1228.
7. Matsushita T., Rama A., Charolidi N., Dupont E., Severs N.J. Relationship of connexin43 expression to phenotypic modulation in cultured human aortic smooth muscle cells. Eur J Cell Biol 2007, 86:617-628.
8. Song M., Yu X., Cui X., Zhu G., Zhao G., Chen J., et al. Blockade of connexin 43 hemichannels reduces neointima formation after vascular injury by inhibiting proliferation and phenotypic modulation of smooth muscle cells. Exp Biol Med (Maywood) 2009, 234:1192-1200.
9. Gerdes N., Sukhova G.K., Libby P., Reynolds R.S., Young J.L., Schonbeck U. Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for atherogenesis. J Exp Med 2002, 195:245-257.
10. Yamagami H., Kitagawa K., Hoshi T., Furukado S., Hougaku H., Nagai Y., et al. Associations of serum IL-18 levels with carotid intima-media thickness. Arterioscler Thromb Vasc Biol 2005, 25:1458-1462.
11. Whitman S.C., Ravisankar P., Daugherty A. Interleukin-18 enhances atherosclerosis in apolipoprotein E(-/-) mice through release of interferon-gamma. Circ Res 2002, 90:E34-E38.
12. Mallat Z., Corbaz A., Scoazec A., Besnard S., Leseche G., Chvatchko Y., et al. Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulation 2001, 104:1598-1603.
13. Chandrasekar B., Mummidi S., Valente A.J., Patel D.N., Bailey S.R., Freeman G.L., et al. The pro-atherogenic cytokine interleukin-18 induces CXCL16 expression in rat aortic smooth muscle cells via MyD88, interleukin-1 receptor-associated kinase, tumor necrosis factor receptor-associated factor 6, c-Src, phosphatidylinositol 3-kinase, Akt, c-Jun N-terminal kinase, and activator protein-1 signaling. J Biol Chem 2005, 280:26263-26277.
14. Chandrasekar B., Mummidi S., Mahimainathan L., Patel D.N., Bailey S.R., Imam S.Z., et al. Interleukin-18-induced human coronary artery smooth muscle cell migration is dependent on NF-kappaB- and AP-1-mediated matrix metalloproteinase-9 expression and is inhibited by atorvastatin. J Biol Chem 2006, 281:15099-15109.
15. Dichtl W., Dulak J., Frick M., Alber H.F., Schwarzacher S.P., Ares M.P., et al. HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2003, 23:58-63.
16. Eccles K.A., Sowden H., Porter K.E., Parkin S.M., Homer-Vanniasinkam S., Graham A.M. Simvastatin alters human endothelial cell adhesion molecule expression and inhibits leukocyte adhesion under flow. Atherosclerosis 2008, 200:69-79.
17. Indolfi C., Cioppa A., Stabile E., Di Lorenzo E., Esposito G., Pisani A., et al. Effects of hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin on smooth muscle cell proliferation in vitro and neointimal formation in vivo after vascular injury. J Am Coll Cardiol 2000, 35:214-221.
18. Hidaka Y., Eda T., Yonemoto M., Kamei T. Inhibition of cultured vascular smooth muscle cell migration by simvastatin (MK-733). Atherosclerosis 1992, 95:87-94.
19. Dol F., Mares A., Herbert J. Simvastatin inhibits myointimal hyperplasia following carotid artery injury in cholesterol-fed rabbits. Blood Coagul Fibrinolysis 1996, 7:772-778.
20. Kobayashi M., Ishida F., Takahashi T., Taguchi K., Watanabe K., Ohmura I., et al. Preventive effect of MK-733 (simvastatin), an inhibitor of HMG-CoA reductase, on hypercholesterolemia and atherosclerosis induced by cholesterol feeding in rabbits. Jpn J Pharmacol 1989, 49:125-133.
21. Kastelein J.J., Sager P.T., de Groot E., Veltri E. Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial. Am Heart J 2005, 149:234-239.
22. Wang L.H., Chen J.Z., Sun Y.L., Zhang F.R., Zhu J.H., Hu S.J., et al. Statins reduce connexin40 and connexin43 expression in atherosclerotic aorta of rabbits. Int J Cardiol 2005, 100:467-475.
23. Shao P.L., Chiu C.C., Yuen C.M., Chua S., Chang L.T., Sheu J.J., et al. Shock wave therapy effectively attenuates inflammation in rat carotid artery following endothelial denudation by balloon catheter. Cardiology 2010, 115:130-144.
24. Kao Y.H., Chen C.L., Jawan B., Chung Y.H., Sun C.K., Kuo S.M., et al. Upregulation of hepatoma-derived growth factor is involved in murine hepatic fibrogenesis. J Hepatol 2010, 52:96-105.
25. Eugenin E.A., Branes M.C., Berman J.W., Saez J.C. TNF-alpha plus IFN-gamma induce connexin43 expression and formation of gap junctions between human monocytes/macrophages that enhance physiological responses. J Immunol 2003, 170:1320-1328.
26. Liao Y., Regan C.P., Manabe I., Owens G.K., Day K.H., Damon D.N., et al. Smooth muscle-targeted knockout of connexin43 enhances neointimal formation in response to vascular injury. Arterioscler Thromb Vasc Biol 2007, 27:1037-1042.
27. Laird D.W. Connexin phosphorylation as a regulatory event linked to gap junction internalization and degradation. Biochim Biophys Acta 2005, 1711:172-182.
28. Laufs U., Marra D., Node K., Liao J.K. 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1). J Biol Chem 1999, 274:21926-21931.
29. Blanco-Colio L.M., Villa A., Ortego M., Hernandez-Presa M.A., Pascual A., Plaza J.J., et al. 3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation. Atherosclerosis 2002, 161:17-26.
30. Sahar S., Dwarakanath R.S., Reddy M.A., Lanting L., Todorov I., Natarajan R. Angiotensin II enhances interleukin-18 mediated inflammatory gene expression in vascular smooth muscle cells: a novel cross-talk in the pathogenesis of atherosclerosis. Circ Res 2005, 96:1064-1071.
31. Yoo J.K., Kwon H., Khil L.Y., Zhang L., Jun H.S., Yoon J.W. IL-18 induces monocyte chemotactic protein-1 production in macrophages through the phosphatidylinositol 3-kinase/Akt and MEK/ERK1/2 pathways. J Immunol 2005, 175:8280-8286.
32. Dunn C.A., Su V., Lau A.F., Lampe P.D. Activation of akt, not connexin 43 protein ubiquitination, regulates gap junction stability. J Biol Chem 2011, 287:2600-2607.
33. Knapp A.C., Huang J., Starling G., Kiener P.A. Inhibitors of HMG-CoA reductase sensitize human smooth muscle cells to Fas-ligand and cytokine-induced cell death. Atherosclerosis 2000, 152:217-227.